Cheryl Li

1.1k total citations
23 papers, 838 citations indexed

About

Cheryl Li is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Cheryl Li has authored 23 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Cheryl Li's work include Chronic Lymphocytic Leukemia Research (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Eosinophilic Esophagitis (2 papers). Cheryl Li is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Eosinophilic Esophagitis (2 papers). Cheryl Li collaborates with scholars based in United States, Japan and United Kingdom. Cheryl Li's co-authors include Walt F. Lima, Stanley T. Crooke, Thomas J. Feuerstein, John P. Gibbs, Emily Tate, Lori M. Roberts, Noa Zerangue, Bo Feng, Mark S. Warren and Bill J. Smith and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Cheryl Li

22 papers receiving 819 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cheryl Li United States	11	383	189	168	110	103	23	838
Raouf Fetni Canada	15	481 1.3×	220 1.2×	67 0.4×	153 1.4×	52 0.5×	34	857
Khoa Nguyen United States	17	399 1.0×	216 1.1×	172 1.0×	38 0.3×	45 0.4×	38	976
Masayo Hosokawa Japan	15	471 1.2×	252 1.3×	151 0.9×	156 1.4×	41 0.4×	21	964
Kirsten Canté-Barrett Netherlands	17	529 1.4×	221 1.2×	346 2.1×	86 0.8×	26 0.3×	33	1.1k
Ilan Ifergan Israel	18	390 1.0×	397 2.1×	212 1.3×	31 0.3×	251 2.4×	20	1.1k
Ute Ungethüm Germany	15	503 1.3×	141 0.7×	143 0.9×	31 0.3×	147 1.4×	25	874
Brian Niland United States	13	467 1.2×	141 0.7×	531 3.2×	92 0.8×	368 3.6×	18	1.4k
Mat Rousch Netherlands	15	372 1.0×	137 0.7×	309 1.8×	133 1.2×	33 0.3×	23	922
Antonietta Picascia Italy	16	378 1.0×	59 0.3×	113 0.7×	57 0.5×	28 0.3×	35	794
Joanna D. Stewart Germany	18	770 2.0×	128 0.7×	87 0.5×	62 0.6×	14 0.1×	27	1.1k

Countries citing papers authored by Cheryl Li

Since Specialization

Citations

This map shows the geographic impact of Cheryl Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheryl Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheryl Li more than expected).

Fields of papers citing papers by Cheryl Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheryl Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheryl Li. The network helps show where Cheryl Li may publish in the future.

Co-authorship network of co-authors of Cheryl Li

This figure shows the co-authorship network connecting the top 25 collaborators of Cheryl Li. A scholar is included among the top collaborators of Cheryl Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheryl Li. Cheryl Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Cheryl, Scott Van Wart, Lili Yang, et al.. (2025). Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling of Serum M‐Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma. Clinical and Translational Science. 18(7). e70296–e70296. 1 indexed citations

Barratt, Jonathan, et al.. (2024). Safety, Tolerability, and Efficacy of Mezagitamab (TAK-079) as Add-On to Standard of Care Therapy in Individuals with Primary IgA Nephropathy: Interim Results from an Open-Label Phase 1b Study. Journal of the American Society of Nephrology. 35(10S). 2 indexed citations

Vogl, Dan T., Shebli Atrash, Sarah A. Holstein, et al.. (2024). Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma. Blood. 145(9). 944–955. 1 indexed citations

Pratz, Keith W., Jason Kaplan, Moshe Levy, et al.. (2022). A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 108(3). 705–716. 10 indexed citations

Johnson, Melissa L., David Sommerhalder, Navid Hafez, et al.. (2022). Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2503–2503.

Li, Cheryl, Kenny J. Watson, Shining Wang, Paul M. Diderichsen, & Neeraj Gupta. (2022). Population Pharmacokinetics of Mivavotinib (TAK‐659), a Dual Spleen Tyrosine Kinase and FMS‐Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies. The Journal of Clinical Pharmacology. 63(3). 326–337. 1 indexed citations

Li, Cheryl, et al.. (2021). Obesity protects against sepsis-induced and norepinephrine-induced white adipose tissue browning. American Journal of Physiology-Endocrinology and Metabolism. 321(3). E433–E442. 10 indexed citations

Danto, Spencer I., Ravi Shankar Prasad Singh, Cheryl Li, et al.. (2019). Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. Arthritis Research & Therapy. 21(1). 269–269. 44 indexed citations

Chen, Xiaoying, Cheryl Li, Reginald B. Ewesuedo, & Donghua Yin. (2019). Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 84(1). 83–92. 11 indexed citations

10.

Phillips, Tycel, Gilles Salles, Daniel J. Landsburg, et al.. (2019). A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 5310–5310. 2 indexed citations

11.

Chang, Cheng, Kari R. Fonseca, Cheryl Li, et al.. (2018). Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition. Molecular Pharmacology. 94(2). 823–833. 7 indexed citations

12.

Danese, Silvio, Séverine Vermeire, Paul Hellstern, et al.. (2017). Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 68(1). 40–48. 136 indexed citations

13.

Wallace, Daniel J., Vibeke Strand, Joan T. Merrill, et al.. (2016). Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Annals of the Rheumatic Diseases. 76(3). 534–542. 98 indexed citations

14.

Lima, Walt F., Timothy A. Vickers, Josh G. Nichols, Cheryl Li, & Stanley T. Crooke. (2014). Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides. PLoS ONE. 9(7). e101752–e101752. 39 indexed citations

15.

Kozielska, Magdalena, Martin Johnson, Venkatesh Pilla Reddy, et al.. (2012). Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats. Pharmaceutical Research. 29(7). 1932–1948. 27 indexed citations

16.

Lima, Walt F., Thazha P. Prakash, Heather Murray, et al.. (2012). Single-Stranded siRNAs Activate RNAi in Animals. Cell. 150(5). 883–894. 205 indexed citations

17.

Johnson, Martin, Magdalena Kozielska, Venkatesh Pilla Reddy, et al.. (2011). Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D2 Receptor Occupancy of Olanzapine in Rats. Pharmaceutical Research. 28(10). 2490–2504. 15 indexed citations

18.

Warren, Mark S., Noa Zerangue, Lori M. Roberts, et al.. (2009). Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacological Research. 59(6). 404–413. 191 indexed citations

19.

Cordes, Jason, Cheryl Li, R.J. Austin-LaFrance, et al.. (2009). Translation between in vitro inhibition of the cardiac Nav1.5 channel and pre-clinical and clinical QRS widening. Journal of Pharmacological and Toxicological Methods. 60(2). 221–221. 12 indexed citations

20.

Patel, Snahel, Robin L. Roof, Bradley J. Snyder, et al.. (2008). Identification and SAR around N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-[1,4]diazepan-1-yl]-ethyl}-2-phenoxy-nicotinamide, a selective α2C adrenergic receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 18(20). 5689–5693. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact